4 - Vivani Medical, Inc. (0001266806) (Issuer)

4 - Vivani Medical, Inc. (0001266806) (Issuer)

3 - Vivani Medical, Inc. (0001266806) (Issuer)

4 - Vivani Medical, Inc. (0001266806) (Issuer)

4 - Vivani Medical, Inc. (0001266806) (Issuer)

4 - Vivani Medical, Inc. (0001266806) (Issuer)

4 - Vivani Medical, Inc. (0001266806) (Issuer)

4 - Vivani Medical, Inc. (0001266806) (Issuer)

4 - Vivani Medical, Inc. (0001266806) (Issuer)

4 - Vivani Medical, Inc. (0001266806) (Issuer)

4 - Vivani Medical, Inc. (0001266806) (Issuer)

4 - Vivani Medical, Inc. (0001266806) (Issuer)

4 - Vivani Medical, Inc. (0001266806) (Issuer)

4 - Vivani Medical, Inc. (0001266806) (Issuer)

4 - Vivani Medical, Inc. (0001266806) (Issuer)

4 - Vivani Medical, Inc. (0001266806) (Issuer)

4 - Vivani Medical, Inc. (0001266806) (Issuer)

4 - Vivani Medical, Inc. (0001266806) (Issuer)

4 - Vivani Medical, Inc. (0001266806) (Issuer)

4 - Vivani Medical, Inc. (0001266806) (Issuer)

MIAMI, July 15, 2026 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 94th Emerging Growth Conference on July 15 & 16, 2026. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: Questions@EmergingGrowth.com For updates, follow us on Twitter Presenting Today – Wednesday July 15, 2026 11:00Virtual Lobby opens.Register for the Conference. If you already registered

ALAMEDA, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ:VANI) (the "Company" or "Vivani"), an innovative, biopharmaceutical company developing novel, miniature, GLP-1 drug implants with once- or twice-yearly administration, today announced that it will present at the Emerging Growth Conference on July 15, 2026. Vivani invites individual and institutional investors as well as advisors and analysts to attend its interactive presentation at the Emerging Growth Conference. Vivani CEO Adam Mendelsohn, Ph.D., will deliver a company update and may subsequently open the floor to questions. Please submit questions in advance to Questions@EmergingGrowth.com. Vivani will be

MIAMI, July 14, 2026 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 94th Emerging Growth Conference on July 15 & 16, 2026. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: Questions@EmergingGrowth.com For updates, follow us on Twitter Day 1 - WednesdayJuly 15, 2026 11:00Virtual Lobby opens.Register for the Conference. If you already registered, go back to

ALAMEDA, Calif., July 07, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ:VANI) ("Vivani" or the "Company"), an innovative, biopharmaceutical company developing novel, ultra long-acting drug implants, today announced the signing of a new agreement with Novo Nordisk to enable Novo Nordisk to evaluate NPM-139, the Company’s semaglutide drug implant. NPM-139, which utilizes Vivani’s NanoPortal™ platform technology, is under development for chronic weight management. There are no exclusivity provisions for NPM-139, or Vivani’s proprietary NanoPortal technology associated with this agreement. Adam Mendelsohn, Ph.D., Vivani President and CEO, stated: "The new agreement announced today s

ClearOne, Inc. (NASDAQ:CLRO) ("ClearOne") announced today that it has entered into a definitive agreement and plan of merger (the "Agreement") among its wholly-owned subsidiary ("MergerSub"), Vivani Medical, Inc. (NASDAQ:VANI; "Vivani"), "Vivani"), and Cortigent, Inc. ("Cortigent"), a wholly-owned subsidiary of Vivani, pursuant to which Cortigent will become a wholly-owned subsidiary of ClearOne (the "Transaction") upon consummation. In connection with the Transaction, ClearOne has agreed to file a registration statement on Form S-1 to raise a minimum of $10,000,000 and a maximum of $15,000,000 (the "Financing") concurrently with the closing of the Transaction (the "Closing"). "I am exc

Vivani proposes to merge Cortigent, Inc. with a wholly owned subsidiary of ClearOne, Inc. (NASDAQ:CLRO), and change the listed company’s name and ticker to Cortigent Holdings, Inc. (d/b/a Cortigent) and "CRGT" Cortigent is a leading developer of brain computer interface ("BCI") devices based on precision neurostimulation technology ALAMEDA, Calif., July 02, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ:VANI) ("Vivani"), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, announced today that it has entered into a definitive agreement and plan of merger (the "Agreement") among its wholly owned subsidiary Cortigent, Inc. ("Cortigent"),

ALAMEDA, Calif., June 26, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ:VANI) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today announced the appointment of August Moretti to its board of directors. Concurrent with this appointment, the Company announced the retirement of Dr. Dean Baker from the board. "We are pleased to welcome August Moretti to our board at this transformative stage for Vivani," said Gregg Williams, Chairman of the Board. "His expertise will be instrumental as we advance our lead semaglutide implant, NPM-139, through clinical-stage development and continue to leverage our propriet

ALAMEDA, Calif., June 25, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ:VANI) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, announced today that it has received approval from Bellberry, a human research ethics committee (HREC) in Australia to initiate SLIM-1™, a Phase 1 clinical trial of NPM-139, a semaglutide implant. Vivani CEO Adam Mendelsohn, Ph.D., stated, "HREC approval to initiate SLIM-1 in Australia marks an important moment for our Company, clearing the way for near-term, mid-2026, initiation. We are eager to conduct this Phase 1 clinical trial of NPM-139, a semaglutide implant, building on t

ALAMEDA, Calif., June 22, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ:VANI) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, announced today that CEO Adam Mendelsohn, Ph.D., will present a company overview and host investor and partner meetings at the 2026 BIO International Convention taking place this week in San Diego, California. Details of Dr. Mendelsohn’s presentation are as follows: Date: Wednesday, June 24, 2026Time: 2:15 p.m. Pacific Time Location: Theater 3, San Diego Convention Center More information about the 2026 BIO International Convention can be found at https://convention.bio.org/.

ALAMEDA, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ:VANI) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, announced today that CEO Adam Mendelsohn, Ph.D., will present a company overview and host investor and partner meetings at the Jefferies Global Healthcare Conference taking place June 2-4, 2026 in New York, New York. Details of Dr. Mendelsohn's presentation are as follows: Date: Thursday, June 4, 2026Time: 11:05 a.m. - 11:35 a.m. Eastern Time Location: New York Marriott Marquis, 1535 Broadway Following the presentation, a replay will be available for 90 days on the Investors sec

ALAMEDA, Calif., June 26, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ:VANI) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today announced the appointment of August Moretti to its board of directors. Concurrent with this appointment, the Company announced the retirement of Dr. Dean Baker from the board. "We are pleased to welcome August Moretti to our board at this transformative stage for Vivani," said Gregg Williams, Chairman of the Board. "His expertise will be instrumental as we advance our lead semaglutide implant, NPM-139, through clinical-stage development and continue to leverage our propriet

Company plans rapid advancement of semaglutide implant NPM-139, following positive weight loss data from an ongoing preclinical study of NPM-139 and promising results from the LIBERATE-1 Phase 1 clinical study of NPM-115 New $10M equity financing to enable accelerated development of NPM-139 while securing financial position into the second half of 2026 Vivani to spin off Cortigent, Inc., a division of the Company that develops brain implant devices to help patients recover critical body functions, as an independent publicly traded company ALAMEDA, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ:VANI) ("Vivani" or the "Company"), a biopharmaceutical company

Cortigent is a leading developer of brain implant devices based on precision neurostimulation technology. It is the only company to have obtained FDA approval of a device providing artificial vision for the profoundly blind Cortigent's new Orion® artificial vision system, developed to treat blindness caused by common conditions, has successfully completed a 6-year Early Feasibility Study Cortigent is developing a new medical device aimed at improving recovery of arm and hand motion in patients with paralysis due to stroke Vivani to sharpen focus on development of miniature, ultra long-acting GLP-1 implants for weight loss management and treatment of type 2 diabetes with once or twice-year

SC 13D/A - Vivani Medical, Inc. (0001266806) (Subject)

SC 13D - Vivani Medical, Inc. (0001266806) (Subject)